Meissa obtains $30M Series A from Morningside to test synthetic biology approach to 'elusive' RSV vaccines
Morningside Ventures has written a $30 million check to fuel an early-stage exploration of a new kind of respiratory syncytial virus.
Meissa Vaccines has chosen a field in which the most high-profile recent development might be the demise of Gates Foundation-backed NovaVax, after its candidate failed to protect either infants or the elderly from respiratory tract infections caused by RSV. AstraZeneca has had more luck with an antibody approach, but other disappointments abound.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.